Nathan McCutcheon

Money Moves

As of October 2026: Will lead integration of IntraBio as a subsidiary

Shionogi agreed to pay $2 billion for IntraBio, a Texas biotech whose single marketed drug treats two inherited neurological disorders. The deal, announced October 5, hands the Osaka-based drugmaker a product that weeks earlier became the first approved treatment for ataxia-telangiectasia, a rare and fatal genetic disease.

Updated Oct 9